0      0

W104 - Development of Homogeneous Dual-cell Based T-cell Dependent Cellular Cytotoxicity Assays

‐ Apr 29, 2020 11:40am

Protein-based therapeutics have undergone an evolution since the first products were marketed over 30 years ago. These early modalities were directed towards interaction with a single target while currently, many protein-based therapeutics are being designed to encompass more than one functional domain and are engineered to interact with more than one target. The Bispecific T-cell Engager (BiTE®) therapeutic class are comprised of two single chain variable fragments (scFv) from two distinct monoclonal antibodies which are connected by a short linker. One scFv is directed against cluster of differentiation 3 (CD3) on T cells, while the other is directed against a cell-surface tumor antigen. In vivo, the engagement of the BiTE® molecule with the T cell and the tumor cell induces the formation of a cytolytic synapse resulting in specific lysis of the tumor cells. In vitro, T cell dependent cellular cytotoxicity (TDCC) assays are used to demonstrate this mechanism of action. Traditional dual-cell based cytotoxicity assays have included labelling target cells with either dyes or radioactivity rendering the assay format to be non-homogeneous. We have developed and implemented homogeneous dual cell-based TDCC assays by employing the use of target cells that constitutively express luciferase as a surrogate marker of viable cell number. By utilizing this format for target cells, the change in viable target cell number can be readily detected by addition of a reagent that contains detergent to lyse the cells, and luciferin, a substrate for luciferase. This talk will highlight some of the important elements to consider during assay development.


You must be logged in and own this session in order to post comments.